BPG is committed to discovery and dissemination of knowledge
Home / Archive / Volume 31, Issue 33
  • This Article
Peer-Review Report of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Supplementary Materials of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Observational Study
©The Author(s) 2025.
World J Gastroenterol. Sep 7, 2025; 31(33): 108872
Published online Sep 7, 2025. doi: 10.3748/wjg.v31.i33.108872
Figure 4
Full Size Figure Download Figure
Figure 4 Clinicians’ comparative perception of methotrexate vs azathioprine for Crohn’s disease treatment. A: Perceptions according to methotrexate (MTX) non-prescribers; B: Perceptions according to MTX prescribers. The question posed was: "How do you rate methotrexate compared with azathioprine in the treatment of Crohn’s disease?" (Single answer question). Respondents compared MTX and azathioprine across dimensions such as efficacy, adherence, short-term and long-term tolerance, and ease of use.
Write to the Help Desk
Copyright © 1993-2026 Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA. All rights reserved, including rights relating to text and data mining, AI training, and similar technologies. For open-access content, the applicable copyright and licensing terms govern.